In type 2 diabetic mellitus, glucose-dependent insulinotropic polypeptide (GIP) secretion is increased, but its insulinotropic effect is severely reduced, perhaps as a result of reduced GIP receptor expression or reduced β-cell sensitivity to GIP (1, 2). In addition, many studies demonstrated a progressive decline in postprandial glucagon-like peptide-1 (GLP-1) secretion, where individuals with type 2 diabetes demonstrate the greatest impairment in GLP-1 secretion (3,4). This difference has been called the incretin effect. Although GLP-1 has been used as a therapeutic drug, the clinical utility of native GLP-1 is limited by its short half-life (within 2 min) due to its rapid degradation to inactive metabolites by the enzyme dipeptidyl peptidase-4 (DPP-4) (5 -8). Therefore, DPP-4 inhibitor is also useful target for the therapy of type 2 diabetic mellitus. Sitagliptin, vildagliptin, saxagliptin, and alogliptin have been used in the clinic.On the other hand, α-lactoalbumin, β-lactoglobulin, and lactoferrin, which are major protein components of bovine milk whey, have been known to have many pharmacological functions such as anti-hypertensive, anti-inflammatory, analgesic, and insulinotropic properties (9). We also reported anti-inflammatory and analgesic activity of α-lactoalbumin (10). Milk products are powerful acute stimulants of insulin secretion (11,12) and have the ability to enhance the insulin response when supplied in a mixed meal (13). Frid et al. (14) reported that acute administration of whey protein-supplemented meals to individuals with type 2 diabetes was associated with significant increments in postprandial insulin responses and higher levels of GIP but not GLP-1. Recently, Tulipano et al. (15) reported that Ile-Pro-Ala, a DPP-4 inhibitor, was isolated from the hydrolysates of β-lactoglobulin, the major whey protein. After oral administration, milk protein is transferred to the duodenum from the stomach and digested by trypsin secreted from the pancreas. We already tested the effects of alpha-lactoalbumin and trypsin-treated alpha-lactoalbumin on DPP-4 activity and found that these proteins did not show any inhibitory effect on DPP-4. However, trypsin-treated β-lactoglobulin showed inhibitory effect on it. Then, we tested the hypoglycemic efficacy of trypsin-treated β-lactoglobulin in the oral glucose tolerance test using mice. Next we isolated the hypoglycemic peptide having DPP-4 inhibiting activity and identified the active amino acid sequence. Research and Development, Meiji Corporation, Ltd., 540 Naruda, Odawara, Kanagawa 250-0862, Japan Received May 12, 2011; Accepted June 29, 2011 Abstract. Trypsin-treated β-lactoglobulin significantly decreased the glucose level after an oral glucose tolerance test using mice. We performed the present study to identify the active peptide inhibiting dipeptidyl peptidase-4 from trypsin-treated β-lactoglobulin. Trypsin-treated β-lactoglobulin showed a concentration-dependent inhibition for dipeptidyl peptidase-4, with an IC 50 value of 210 μM, althoug...